BR112012003111A8 - Métodos para tratar iontoforeticamente náusea e enxaqueca - Google Patents

Métodos para tratar iontoforeticamente náusea e enxaqueca

Info

Publication number
BR112012003111A8
BR112012003111A8 BR112012003111A BR112012003111A BR112012003111A8 BR 112012003111 A8 BR112012003111 A8 BR 112012003111A8 BR 112012003111 A BR112012003111 A BR 112012003111A BR 112012003111 A BR112012003111 A BR 112012003111A BR 112012003111 A8 BR112012003111 A8 BR 112012003111A8
Authority
BR
Brazil
Prior art keywords
migraine
methods
iontophoretically
treat nausea
nausea
Prior art date
Application number
BR112012003111A
Other languages
English (en)
Other versions
BR112012003111A2 (pt
Inventor
B Sebree Terri
Pierce Mark
O'neil Carol
Original Assignee
Nupathe Inc
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nupathe Inc, Teva Pharmaceuticals Int Gmbh filed Critical Nupathe Inc
Publication of BR112012003111A2 publication Critical patent/BR112012003111A2/pt
Publication of BR112012003111A8 publication Critical patent/BR112012003111A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)

Abstract

MÉTODOS PARA TRATAR IONTOFORETICAMENTE NÁUSEA E ENXAQUECA. A presente invenção refere-se a métodos para tratar náusea e enxaqueca por administração iontoforeticamente de compostos de triptano que são proporcionados.
BR112012003111A 2009-08-10 2010-08-10 Métodos para tratar iontoforeticamente náusea e enxaqueca BR112012003111A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23261709P 2009-08-10 2009-08-10
US25679609P 2009-10-30 2009-10-30
US35830010P 2010-06-24 2010-06-24
PCT/US2010/045045 WO2011019732A1 (en) 2009-08-10 2010-08-10 Methods for iontophoretically treating nausea and migraine

Publications (2)

Publication Number Publication Date
BR112012003111A2 BR112012003111A2 (pt) 2015-10-13
BR112012003111A8 true BR112012003111A8 (pt) 2017-10-10

Family

ID=43586432

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003111A BR112012003111A8 (pt) 2009-08-10 2010-08-10 Métodos para tratar iontoforeticamente náusea e enxaqueca

Country Status (11)

Country Link
US (2) US8845612B2 (pt)
EP (1) EP2464234A4 (pt)
JP (2) JP6116246B2 (pt)
CN (3) CN105748401A (pt)
AU (1) AU2010282660B2 (pt)
BR (1) BR112012003111A8 (pt)
CA (1) CA2770211A1 (pt)
EA (1) EA201270227A1 (pt)
IL (1) IL217935A0 (pt)
NZ (1) NZ598622A (pt)
WO (1) WO2011019732A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
BR112012003111A8 (pt) 2009-08-10 2017-10-10 Nupathe Inc Métodos para tratar iontoforeticamente náusea e enxaqueca
EP3416618A1 (en) 2016-02-19 2018-12-26 ZP Opco, Inc. Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US11660264B2 (en) 2017-08-23 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
US11660265B2 (en) 2018-06-28 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4856188A (en) 1984-10-12 1989-08-15 Drug Delivery Systems Inc. Method for making disposable and/or replenishable transdermal drug applicators
US5651768A (en) 1983-08-18 1997-07-29 Drug Delivery Systems, Inc. Transdermal drug applicator and electrodes therefor
US5605536A (en) 1983-08-18 1997-02-25 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
US4822802A (en) 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US4927408A (en) 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
DE4014913C2 (de) 1990-05-10 1996-05-15 Lohmann Therapie Syst Lts Miniaturisiertes transdermales therapeutisches System für die Iontophorese
JP3488466B2 (ja) 1992-06-02 2004-01-19 アルザ・コーポレーション 電気駆動式薬物投与デバイス
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5458569A (en) 1993-06-08 1995-10-17 Becton Dickinson And Company Wearable iontophoresis system
US5533971A (en) 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
ATE211655T1 (de) 1993-09-22 2002-01-15 Hisamitsu Pharmaceutical Co Iontophoresematrix
US5697896A (en) 1994-12-08 1997-12-16 Alza Corporation Electrotransport delivery device
IE960312A1 (en) 1995-06-02 1996-12-11 Alza Corp An electrotransport delivery device with voltage boosting¹circuit
US6216033B1 (en) 1996-05-22 2001-04-10 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6425892B2 (en) 1995-06-05 2002-07-30 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
ATE263597T1 (de) 1995-06-05 2004-04-15 Alza Corp Vorrichtung zur transdermalen iontophoretischen verabreichung von fentanyl und sufentanil
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5941843A (en) 1996-07-12 1999-08-24 Empi, Inc. Iontophoresis electrode
US5882677A (en) 1997-09-30 1999-03-16 Becton Dickinson And Company Iontophoretic patch with hydrogel reservoir
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
US6421561B1 (en) 1999-12-30 2002-07-16 Birch Point Medical, Inc. Rate adjustable drug delivery system
IT1319210B1 (it) 2000-10-13 2003-09-26 Italiano Biochimico Lisapharma Pellicola per la somministrazione dermica e transdermica di principiattivi.
US6653014B2 (en) 2001-05-30 2003-11-25 Birch Point Medical, Inc. Power sources for iontophoretic drug delivery systems
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
AU2003280136A1 (en) 2002-06-28 2004-01-19 Alza Corporation A reservoir for use in an electrotransport drug delivery device
US6745071B1 (en) 2003-02-21 2004-06-01 Birch Point Medical, Inc. Iontophoretic drug delivery system
US20040242770A1 (en) 2003-04-16 2004-12-02 Feldstein Mikhail M. Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
US8734421B2 (en) 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
US20050228336A1 (en) 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
US7856263B2 (en) 2005-04-22 2010-12-21 Travanti Pharma Inc. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
WO2007041300A2 (en) 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoresis method and apparatus for systemic delivery of active agents
JP2009509685A (ja) 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 損傷組織の治癒を増強するための血管新生因子の送達のためのイオントフォレーシス装置及び方法
NZ610790A (en) * 2006-04-13 2015-05-29 Nupathe Inc Transdermal methods and systems for the delivery of anti-migraine compounds
US8366600B2 (en) 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
US8155737B2 (en) 2008-06-19 2012-04-10 Nupathe, Inc. Pharmacokinetics of iontophoretic sumatriptan administration
BR112012003111A8 (pt) 2009-08-10 2017-10-10 Nupathe Inc Métodos para tratar iontoforeticamente náusea e enxaqueca

Also Published As

Publication number Publication date
CA2770211A1 (en) 2011-02-17
EA201270227A1 (ru) 2012-10-30
US9592291B2 (en) 2017-03-14
EP2464234A4 (en) 2013-01-02
CN105796533A (zh) 2016-07-27
EP2464234A1 (en) 2012-06-20
BR112012003111A2 (pt) 2015-10-13
WO2011019732A1 (en) 2011-02-17
US8845612B2 (en) 2014-09-30
AU2010282660B2 (en) 2015-06-25
NZ598622A (en) 2014-02-28
JP2013501796A (ja) 2013-01-17
CN102573489A (zh) 2012-07-11
JP2016014028A (ja) 2016-01-28
US20150032083A1 (en) 2015-01-29
CN105748401A (zh) 2016-07-13
IL217935A0 (en) 2012-03-29
US20110066100A1 (en) 2011-03-17
AU2010282660A1 (en) 2012-03-08
JP6116246B2 (ja) 2017-04-19

Similar Documents

Publication Publication Date Title
BR112012003111A8 (pt) Métodos para tratar iontoforeticamente náusea e enxaqueca
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
UA110338C2 (en) Chemical compounds
UA114090C2 (uk) Сполуки, що інгібують металоферменти
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
SV2009003346A (es) Compuestos triciclicos, composiciones y procedimientos.
CR20120001A (es) Compuestos terapeuticos y composiciones
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
EA201171367A1 (ru) Винилиндазолильные соединения
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
UA110813C2 (uk) Лікування ліподистрофії
PA8850801A1 (es) Compuestos útiles para inhibir chk1
ECSP12011585A (es) Compuestos y composiciones para eltratamiento de enfermedades parasitarias
BR112015006037A2 (pt) métodos para tratamento de hcv
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
BR112016014081A2 (pt) Tratamento fotodinâmico de pulso da acne
BR112012022243A2 (pt) terapias inibidoras de autografia baseadas em tioxantona para tratar câncer
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
BR112012012471A2 (pt) compostos, composições e métodos para tratamento de infecções de protozoários
UY32075A (es) Estabilización de preparaciones acuosas de minerales mediante reuterina
CO7121334A2 (es) Formulaciones vesiculares

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2474 DE 05-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI